Kezdőlap・Részvénylista・BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

Lezárt

SzektorEgészségügy

58.79 1.75

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

58.41

Maximum

58.99

Fő mutatók
By Trading Economics
Bevétel	-34M 106M
Értékesítés	-108M 766M
P/E Szektor átlag	41.234 56.269
Egy részvényre jutó nyereség	0.76
Profit margin	13.773
Munkavállalók	3,221
EBITDA	177M 173M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+47.48% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. aug. 3.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	679M 11B
Előző nyitás	57.04
Előző zárás	58.79

Hangulat hírek alapján

By Acuity

34%

66%

89 / 342 Rangsor szerint Healthcare

BioMarin Pharmaceutical Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. júl. 2. 22:51 UTC

Biomarin Pharmaceutical Inc. shares were roughly flat in after-market trading, with no specific news identified. The stock has shown little change since Thursday's close.

2026. júl. 1. 19:36 UTC

Biomarin Pharmaceutical Inc's shares are higher today, reaching a notable intraday high amid broader market caution and no specific company news identified.

2026. jún. 30. 23:51 UTC

No specific news was identified for Biomarin Pharmaceutical Inc. After-market trading has been routine, with shares showing little change since Tuesday's close.

2026. jún. 29. 23:21 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, retracing from earlier gains amid mixed U.S. equity performance and broader inflation concerns.

2026. jún. 26. 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

2026. jún. 25. 23:31 UTC

Biomarin Pharmaceutical shares declined in after-market trading, despite remaining above the 20-day moving average and near the upper end of its one-month range.

2026. jún. 24. 19:41 UTC

Biomarin Pharmaceutical Inc is gaining Wednesday, supported by strong momentum in the Biotechnology sub-sector, despite an earlier decline in the session.

2026. jún. 23. 23:56 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. Broader market sentiment is affected by declines in Asian markets amid tech sector concerns.

2026. jún. 22. 23:56 UTC

Biomarin Pharmaceutical shares showed little change in after-market trading. The stock remains within the middle of its one-month trading range.

2026. jún. 19. 00:01 UTC

Biomarin Pharmaceutical Inc. shares are higher in after-market hours, recovering from earlier lows and reflecting strong performance since Thursday's close.

2026. jún. 18. 23:21 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close despite earlier fluctuations in the session.

2026. jún. 17. 20:08 UTC

Event

Biomarin Pharmaceutical is trading lower amid broader market declines, despite presenting new data on VOXZOGO® and BMN 333 at the ENDO 2026 conference.

2026. jún. 16. 23:41 UTC

Event

Biomarin Pharmaceutical presented new data on investigational therapies at the Endocrine Society Annual Meeting. Shares showed little change during after-market hours.

2026. jún. 15. 13:26 UTC

Biomarin Pharmaceutical Inc is trading higher in pre-market hours, reflecting positive momentum amid a broader upward trend in Asian markets, including a surge in the Nikkei Index.

2026. jún. 13. 00:01 UTC

Biomarin Pharmaceutical Inc shares declined in after-market trading, retracing from earlier gains while remaining above the 20-day moving average. No specific news was identified.

2026. jún. 12. 23:41 UTC

Biomarin Pharmaceutical shares traded lower in after-market hours, reflecting broader market dynamics amid rising bond yields and mixed equity performance.

2026. jún. 11. 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, reaching an early session low. Broader economic news includes an unexpected rise in initial jobless claims.

2026. jún. 10. 20:03 UTC

Biomarin Pharmaceutical shares are lower today, reflecting broader market trends amid volatility. The stock peaked earlier in the session before declining significantly.

2026. jún. 9. 20:03 UTC

Biomarin Pharmaceutical Inc shares are higher, reaching a session high and trading above its 20-day moving average. No specific news was identified for the move.

2026. jún. 8. 22:51 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, reflecting a notable decline despite a broader rebound in US stocks, particularly in the semiconductor sector.

2026. jún. 5. 20:07 UTC

Biomarin Pharmaceutical Inc shares are modestly higher, reflecting broader market gains amid robust job growth data. No specific company news was identified.

2026. jún. 4. 22:31 UTC

Biomarin Pharmaceutical Inc is trading lower in after-market hours amid a broader market decline and rising U.S. Treasury yields impacting biotechnology stocks.

2026. jún. 3. 20:06 UTC

Biomarin Pharmaceutical shares are higher amid broader market strength following a positive ADP Employment Report, which showed job growth exceeding expectations.

2026. jún. 2. 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, continuing a decline since Monday. The stock closed at its lowest point after an early high.

2026. jún. 1. 23:03 UTC

Biomarin Pharmaceutical shares declined in after-market trading, continuing a downward trend since Monday's close, despite remaining above the 20-day moving average.

2026. máj. 29. 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours, reflecting a slight decline since Friday's close amid routine trading patterns.

2026. máj. 28. 22:36 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, reflecting notable movement since Thursday's close amid broader market dynamics and economic data.

2026. máj. 27. 19:41 UTC

Biomarin Pharmaceutical Inc shares are lower Wednesday, reversing recent gains. No specific news was identified to explain the decline since Tuesday's close.

2026. máj. 26. 20:02 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from a recent trend of higher closes amid rising bond yields and no specific company news.

Társak összehasonlítása

Árváltozás

BioMarin Pharmaceutical Inc Előrejelzés

Célár

By TipRanks

47.48% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 87 USD 47.48%

Magas 120 USD

Alacsony 50 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)BioMarin Pharmaceutical Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

20 ratings

Vétel

Tartás

Eladás

20 Wall Street elemző célárain alapulva a(z)BioMarin Pharmaceutical Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

89 / 342 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.